Anavex Life Sciences Corp (AVXL)

[TempePhil]

Tidbit from JPM conference.
Dr.Missling gave maybe a couple nice tidbits.
He says he has the additional results of the PDD study. Also, and more importantly, he describes why the PDD trial data points to expectations of good results in the ALZ trial.

Here is the quote (my bolding):

... Not only were the movement impairment features of Parkinsons improved, but also the cognitive features of these patients were all cognitively impaired in episodic memory, attention, language, visual spatial skills, and executive functions. There is a very precise tool called the CDR system, which is CDR Sum of the Boxes which often gets mixed up, the CDR system captures all these individual elements of cognition very nicely. And we found, on slide number 38, summarizes really nicely, a really close dose response, where the placebo arm declined, as you would expect in a degenerative disease, the medium dose stopped the decline, so it didnt change from baseline, and the high dose that actually improved on a net basis from baseline. So there is a clear shift in the pathology of cognition.

What is very neat about this episodic memory, quality of episodic memory, measure of this system, is that it has been published to correlate very highly with the ADAS-COG, and the ADAS-COG happens to be our primary endpoint in forthcoming Alz study. And what is also important is the Alz study uses the same dose regimen as this Parkinsons Disease Dementia study PDD. I dont want to go over the additional results of the PDD study, but we are moving forward with the discussion with the Parkinson foundations to design pivotal studies respectively for Parkinson now and Parkinson dementia separately obviously, because of the unmet needs for both indications, given the strong data.

Let me now move to...